Compare DRMA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRMA | SBFM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | 9 | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.9M |
| IPO Year | N/A | N/A |
| Metric | DRMA | SBFM |
|---|---|---|
| Price | $1.18 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $7.00 |
| AVG Volume (30 Days) | 47.7K | ★ 18.1M |
| Earning Date | 05-14-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | $650.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.25 |
| 52 Week High | $7.33 | $3.05 |
| Indicator | DRMA | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 65.35 |
| Support Level | $1.13 | $1.27 |
| Resistance Level | $1.40 | $3.05 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 4.35 | 72.32 |
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.